Clinical trial
Prevention of Relapse Study of SR58611A in Improved Patients With Generalized…
NCT00397098 · Sanofi, Industry · Terminated
Key facts
| NCT number | NCT00397098 |
|---|---|
| Title | Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder |
| Official title | A Double-Blind Randomized Withdrawal Study Evaluating the Efficacy and Safety of SR58611A Versus Placebo in the Prevention of Relapse of Anxiety up to 1 Year in Patients With GAD Improved After 12 Weeks of Open Label Treatment With SR58611A. |
| Acronym | VEGA |
| Lead sponsor | Sanofi, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anxiety Disorders |
| Intervention type | Drug |
| Interventions | SR58611A |
| Enrollment | 257 |
| Start date | Nov 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Nov 8, 2006 |
| Last update posted | Mar 12, 2009 |
| Countries | Australia, Chile, France, Germany, Hungary, Italy, Mexico, Russia, Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: